Sugi Predict

Sugi Predict / Compounds / SCHEMBL2943387

SCHEMBL2943387

SCHEMBL2943387

CC(C)(C)OC(=O)N1CCNC(Cc2ccccc2)C1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.54
▸ CA2 P00918 2/20 0.54
▸ CA4 P22748 2/20 0.54
▸ CA9 Q16790 2/20 0.54
▸ JAK2 O60674 1/20 0.49
▸ JAK1 P23458 1/20 0.49
▸ MAPK1 P28482 1/20 0.47
▸ GPR119 Q8TDV5 2/20 0.47
▸ STS P08842 1/20 0.47
▸ USP30 Q70CQ3 4/20 0.44
▸ P2RX7 Q99572 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ ABHD6 Q9BV23 1/20 0.42
▸ DAGLA Q9Y4D2 1/20 0.42
▸ NR1H2 P55055 2/20 0.42
▸ NR1H3 Q13133 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3494790 1.00 CA1 (0.54) CA1CA2CA4CA9JAK2
SCHEMBL17058 1.00 CA1 (0.54) CA1CA2CA4CA9JAK2
SCHEMBL28078174 0.92 CA1 (0.47) CA1CA2CA4CA9JAK2
SCHEMBL28078178 0.92 CA1 (0.47) CA1CA2CA4CA9JAK2
SCHEMBL16583198 0.89 STS (0.54) CA1CA2CA4CA9JAK2
SCHEMBL4972391 0.89 GPR119 (0.47) CA1CA2CA4CA9JAK2
SCHEMBL7047899 0.88 JAK2 (0.47) CA1CA2CA4CA9JAK2
SCHEMBL779489 0.87 NAMPT (0.48) CA1CA2CA4CA9JAK2
SCHEMBL12090083 0.86 JAK2 (0.46) CA1CA2CA4CA9JAK2
SCHEMBL8112498 0.86 GPR119 (0.52) CA1CA2CA4CA9JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036605-A Antagonists of GPR39 proteins 俄勒冈健康科学大学 2026-05-15 — — CN disclosed
US-20240368127-A1 HSD17B13 INHIBITORS AND USES THEREOF FL2022-001, INC. 2024-11-07 — — US disclosed
CN-115745960-B Compound containing quinolinone amide, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2024-08-30 — — CN disclosed
US-20230174484-A1 ANTAGONISTS OF GPR39 PROTEIN UNIV OREGON HEALTH & SCIENCE (US) 2023-06-08 — — US disclosed
CN-115996908-A Antagonists of GPR39 proteins 俄勒冈健康科学大学 2023-04-21 — — CN disclosed
WO-2023043836-A1 HSD17B13 INHIBITORS AND USES THEREOF METACRINE, INC. (US) 2023-03-23 — — WO disclosed
EP-4143163-A1 ANTAGONISTS OF GPR39 PROTEIN Oregon Health & Science University (US) 2023-03-08 — — EP disclosed
CN-115745960-A Quinolinone amide-containing compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2023-03-07 — — CN disclosed
US-20220112187-A1 PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2022-04-14 — — US disclosed
US-20220112187-A1 PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2022-04-14 — — US disclosed
WO-2008019971-A2 ARYLPIPERAZINE DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2008-02-21 — — WO disclosed
WO-2008019971-A2 ARYLPIPERAZINE DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2008-02-21 — — WO disclosed
US-20080045543-A1 Arylpiperazine derivatives and uses thereof ROCHE PALO ALTO LLC 2008-02-21 — — US disclosed
US-7312246-B2 Proteomimetic compounds and methods YALE UNIVERSITY (US) 2007-12-25 — — US disclosed
WO-2007117961-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-10-18 — — WO disclosed
WO-2007094513-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-08-23 — — WO disclosed
US-20050215563-A1 Proteomimetic compounds and methods YALE UNIVERSITY 2005-09-29 — — US disclosed
US-6858600-B2 Proteomimetic compounds and methods YALE UNIVERSITY (US) 2005-02-22 — — US disclosed
WO-2003022214-A2 PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-03-20 — — WO disclosed
US-20030008882-A1 Proteomimetic compounds and methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-01-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112187-A1 PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE SSB, KCNJ1, KCNJ11 CA1 2624/4885CA2 1621/4885CA4 2238/4885
US-20030008882-A1 Proteomimetic compounds and methods PACSIN2, HSP90B1, PHLPP2 CA1 2339/4885CA2 1760/4885CA4 3585/4885
US-20230174484-A1 ANTAGONISTS OF GPR39 PROTEIN GPR39, GPR139, GPR119 CA1 4411/4885CA2 3250/4885CA4 4720/4885
US-20080045543-A1 Arylpiperazine derivatives and uses thereof CYP3A7, CYP3A5, HTR7 CA1 4856/4885CA2 4187/4885CA4 4464/4885
US-20050215563-A1 Proteomimetic compounds and methods PACSIN2, HSP90B1, PHLPP2 CA1 2339/4885CA2 1760/4885CA4 3585/4885
US-20240368127-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B3, HSD17B11, HSD17B1 CA1 2294/4885CA2 2149/4885CA4 2080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.